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Selection in the Ashkenazi Jewish Population
Unlikely—Reply to Zlotogora and Bach
To the Editor:
Zlotogora and Bach (2003 [in this issue]) raise a number
of issues that argue for distinctiveness of the lysosomal
storage diseases (LSDs) versus the nonlysosomal storage
diseases (NLSDs). They note that the four LSDs involve
a similar biochemical pathway. However, our list of
NLSDs also includes three tumor-suppressor genes—
breast cancer type 1 (BRCA1 [MIM 113705]), breast
cancer type 2 (BRCA2 [MIM 600185]), and adenom-
atous polyposis of the colon (APC [MIM 175100])—and
a similar argument could be applied to these. Other pop-
ulations experiencing founder effects also show such pat-
terns. For example, the European Romani population
demonstrates founder effects for three different sensory
neuropathy syndromes (Kalaydjieva et al. 2001). An al-
ternative explanation to heterozygote advantage is de-
tection bias—namely, the recognition of one or two LSDs
in the Ashkenazi Jewish population focused greater at-
tention on the identification of others. For example, it is
likely that additional cancer mutations will also be iden-
tified in the Ashkenazi Jewish population.
Zlotogora and Bach (2003 [in this issue]) suggest that
the number of mutations differs between the LSDs and
NLSDs, with the LSDs having a higher frequency of sec-
ondary mutations. However, our table 1 (Risch et al.
2003) shows this not to be the case. The maximum fre-
quencies for secondary mutations for LSDs are .003, for
Tay-Sachs disease (TSD [MIM 272800]) (mutation 1421),
and .002, for Gaucher disease (GD [MIM 230800]) (mu-
tation 84GG). Secondary mutations with frequencies
as high or higher also exist for factor 11 deficiency (F11
[MIM 264900]), connexin 26 (CX26 [MIM 121011]),
Canavan disease (CAN [MIM 271900]), and cystic fi-
brosis (CF [MIM 219700]). In addition, breast cancer
type 1 (BRCA1 [MIM 113705]) and hyperinsulinism (HI
[MIM 256450]) also have secondary mutations in this
frequency range. There is no difference in number and
frequency distribution for the second-most-frequent mu-
tations between the LSDs and NLSDs. The data in table
1 that we used for this analysis were derived entirely
from the literature and not from Dor Yeshorim and thus
should be representative of the Ashkenazi Jewish popu-
lation generally. The Dor Yeshorim database was used
only for the geographic analyses presented in tables 4 and
5 (Risch et al. 2003). In fact, we showed that it is because
the Dor Yeshorim population derives a greater proportion
of ancestry from Central Europe, versus Eastern Europe,
that its frequency ratio for TSD mutation 1277 versus
mutation 1421 differs from other Ashkenazi Jewish
samples.
The b thalassemia (MIM 141900) example described
by Zlotogora and Bach (2003 [in this issue]) provides a
useful point of discussion. For b thalassemia, a recessive
lethal disease, various mutations have been found at ex-
cessively high frequency (much higher than any reported
in Ashkenazi Jews, as given in our table 1 [Risch et al.
2003]) and in various populations that had been histor-
ically exposed to malaria. The same applies to glucose-
6-phosphate dehydrogenase (G6PD) deficiency (MIM
305900). This is the opposite of the pattern observed for
the LSDs in the Ashkenazim. These diseases are not in-
creased in frequency in any group living historically in
neighboring locales with shared environmental exposures,
even over centuries. Despite potential economic differ-
ences, it seems unlikely that prevalent diseases would not
also have an impact on non-Jews; also, except for founder
mutations, the Ashkenazi population is not that different
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genetically from other white groups. Indeed, it is the
French Canadians who have a comparable frequency of
TSD, also with two distinct founder mutations specific to
that population (but in a geographically dispersed pattern
similar to the Ashkenazi Jews), but who presumably have
shared little in terms of common disease exposures with
the Ashkenazi Jews (De Braekeleer et al. 1992; Hechtman
et al. 1992). On the other hand, another endogamous
population group, the European Romani, who arrived in
Europe at approximately the same time as the Ashke-
nazim and lived in similar locales, also show numerous
founder disease mutations, but none is shared with the
Ashkenazim (Kalaydjieva et al. 2001). What these groups
have in common are founder effects. By contrast, Zlo-
togora and Bach (2003 [in this issue]) seem to be arguing
that the selection factor operating on the Ashkenazim has
spanned centuries and geographic locales yet stayed lim-
ited just to the Ashkenazim. As they point out, however,
all arguments about specific selective factors, such as lung
disease, are speculative and unconfirmed, as opposed to
those involving hemoglobinopathies and malaria.
Zlotogora and Bach (2003 [in this issue]) use the
observation of multiple mutations to infer selective ad-
vantage for etiologically unrelated diseases, such as met-
achromatic leukodystrophy (MIM 250100), Hurler syn-
drome (MIM 252800), hyperoxaluria (MIM 259900),
and ataxia telangiectasia (MIM 208900) in Arabs and
Bardet-Biedl syndrome (MIM 209900) in Bedouins. An
even stronger argument might be applied to BRCA1 in
the Dutch population, which, according to a recent study,
has at least 12 different recurrent mutations (Peelen et al.
1997). It seems implausible that all these disease muta-
tions have undergone selective advantage unique to one
population. We do not agree that the number of mutations
found in a population is a good indication of past selective
forces. Rather, it is aberrantly high mutation frequencies,
despite severe negative selection against homozygotes,
that provide the strongest argument for carrier advantage.
We believe that care needs to be applied in concluding
past selection when disease mutations are specific to single
founder populations. Although we cannot prove that se-
lection has played no role in the LSDs in the Ashkenazi
Jewish population, we have shown that their mutational
distributions—in terms of numbers, frequencies, ages, and
geography—are consistent with genetic drift alone.
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